NanoTag Biotechnologies

Executive Summary

NanoTag Biotechnologies, based in Göttingen, Germany, is a private biotech company specializing in single-domain antibody (nanobody) discovery and recombinant protein production. Founded in 2016, the company provides high-quality affinity reagents for research, diagnostics, and pre-clinical therapeutic development. Its innovative nanobody-based tools are used in super-resolution microscopy, immunofluorescence, and protein purification, positioning it as a key player in the life sciences tool market. NanoTag leverages the unique properties of nanobodies—small size, high stability, and easy recombinant production—to offer superior performance over conventional antibodies. The company serves both academic and industrial customers, with a growing portfolio of validated reagents. While still in the pre-clinical stage for therapeutic applications, NanoTag's expertise in nanobody engineering and its commercial product line provide a solid foundation for future growth. The company's focus on high-demand applications like super-resolution microscopy aligns well with trends in advanced imaging and cellular analysis.

Upcoming Catalysts (preview)

• Q4 2026Partnership with major pharma for therapeutic nanobody development40% success
• Q3 2026Launch of new nanobody-based diagnostic assay kit70% success
• Q2 2027Series A funding round to expand therapeutic pipeline50% success